CARCINOMATOSIS PERITONEAL

Presentación del tema: "CARCINOMATOSIS PERITONEAL"— Transcripción de la presentación:

1 CARCINOMATOSIS PERITONEAL
Area 3 CARCINOMATOSIS PERITONEAL HCUVA, 3 de mayo de 2016

2 Area 3. CARCINOMATOSIS PERITONEAL
PUBLICACIONES PROYECTOS CLÍNICOS PROYECTOS CLÍNICO-BÁSICOS

3 Area 3. CARCINOMATOSIS PERITONEAL
PUBLICACIONES

4 PUBLICACIONES ÚLTIMOS 5 AÑOS
Area 3. CARCINOMATOSIS PERITONEAL PUBLICACIONES ÚLTIMOS 5 AÑOS Cascales P, Lopez V, Gil J and GECOP. Morbidity And Mortality Outcomes After Cytoreductive Surgery And Hyperthermic Intraperitoneal Chemotherapy In Patients Aged 75 Years And Over: Spanish Group Of Peritoneal Cancer Surgery (Gecop) Multicenter Study. Surgical Oncology 2016 (in press) Cascales P, Lopez V, Gil J, et al. Hyperthermic intraperitoneal chemotherapy with paclitaxel or cisplatin in patients with stage III-C/IV ovarian cancer. Is there any difference? . Surgical Oncology (in press) Cascales P, Lopez V, Gil J and GECOP. Survival Outcomes In Patients Older Than 75 Years Old With Peritoneal Colorectal Carcinomatosis After Cytoreductive Surgery And Hyperthermic Intraperitoneal Chemotherapy (Hipec): Multicenter Study Of The Spanish Group Of Peritoneal Cancer Surgery (GECOP). Dis Colon and Rectum (In Press) Cascales P, Gil J, Feliciangeli E, Gil E, Parrilla P. Hipec in ovarian cáncer: Treatment of a new era or is it the end of the pipeline? Gynecol Oncol. 2015;139:363-8 Falcón Araña L, Fuentes-García D, Roca Calvo MJ, Hernández-Palazón J, Gil Martínez J, Cascales Campos PA, Acosta Villegas FJ, Parrilla Paricio P. Alterations in hemostasis during peritonectomy with heated intraperitoneal chemotherapy for peritoneal carcinomatosis. Cir Esp Apr 13. pii: S X(15)00041-X. doi: /j.ciresp F. Machado-Linde, M.L. Sánchez-Ferrer, P. Cascales, A. Torroba, R. Orozco, Y. Silva Sánchez, A. Nieto, G. Fiol. Prevalence of endometriosis in epithelial ovarian cancer. Analysis of the associated clinical features and study on molecular mechanisms involved in the possible causality. Eur J Gynaecol Oncol. 2015;36:21-4 Cascales-Campos P, Gil J, Gil E, Feliciangeli E, López V, Gonzalez AG, Ruiz-Pardo J, Nieto A, Parrilla P. Cytoreduction and HIPEC after neoadjuvant chemotherapy in stage IIIC-IV ovarian cancer. Critical analysis in elderly patients. Eur J Obstet Gynecol Reprod Biol. 2014;179:88-93. Cascales-Campos PA, Gil J, Feliciangeli E, Gil E, González-Gil A, López V, Ruiz-Pardo J, Nieto A, Parrilla JJ, Parrilla P. The Role of Hyperthermic Intraperitoneal Chemotherapy Using Paclitaxel in Platinum-Sensitive Recurrent Epithelial Ovarian Cancer Patients with Microscopic Residual Disease after Cytoreduction. Ann Surg Oncol. 2015;22: doi: /s z Cascales-Campos PA, Gil J, Gil E, Feliciangeli E, González-Gil A, Parrilla JJ, Parrilla P. Treatment of Microscopic Disease with Hyperthermic Intraoperative Intraperitoneal Chemotherapy After Complete Cytoreduction Improves Disease-Free Survival in Patients with Stage IIIC/IV Ovarian Cancer. Ann Surg Oncol Jul;21(7): Cascales Campos P, Gil J, Parrilla P. Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with primary and recurrent advanced ovarian cancer. Eur J Surg Oncol. 2014;40: doi: /j.ejso Cascales Campos PA, Gil Martinez J, Torroba A, Machado F, Parrila Paricio P. Peritoneal dissemination of hepatoid carcinoma of the ovary treated with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy. Case Rep Med. 2013;2013: doi: /2013/

5 PUBLICACIONES ÚLTIMOS 5 AÑOS
Area 3. CARCINOMATOSIS PERITONEAL PUBLICACIONES ÚLTIMOS 5 AÑOS Cascales PA, Gil J, Fuster M, Lloret F, Parrilla P. Enfermedad de Castleman unicéntrica pélvica . Cir Esp. 2012;90: IF: 0.874 Machado-Linde F, Pelegrin P, Sanchez-Ferrer ML, Leon J, Cascales P, Parrilla JJ. 2-Methoxyestradiol in the Pathophysiology of Endometriosis: Focus on Angiogenesis and Therapeutic Potential. Reproductive Sciences 2012 Oct;19: Cascales PA, Gil J, Alarcón CM, Galindo P, Gómez G, Parrilla P. Cirugía del tracto urinario en pacientes con carcinomatosis peritoneal ovárica tratadas con citorreducción y quimioterapia intraperitoneal intraoperatoria hipertérmica. Cir Esp. 2012;90: IF: 0.874 Cascales P, Gil J, Parrilla P. Letter to the editor: Pre-operative evaluation of peritoneal deposits using multidetector computed tomography in ovarian cancer. Some considerations. Br J Radiol. 2011;84:768. IF: 1.314 Cascales Campos PA, Gil J, Parrilla P. Reply to: Use of FDG PET/CT for peritoneal carcinomatosis before hyperthermic intraperitoneal chemotherapy: some considerations. Nucl Med Commun. 2011;32:421. IF: 1.404 Cascales PA, Gil J, Galindo PJ, Machado F, Frutos IM, Paricio PP. Heterogeneity in patients and methods. A problem for hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol. 2011;158: IF: 1.974 Mancebo-González A, Díaz-Carrasco MS, Cascales-Campos P, de la Rubia A, Gil Martínez J. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy associated toxicity in treatment of peritoneal carcinomatosis. Farm Hosp. 2012;36:60-67 Cascales Campos PA, Gil Martí­nez J, Galindo Fernández PJ, Gil Gómez E, Martí­nez Frutos IM, Parrilla Paricio P. Perioperative fast track program in intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery in advanced ovarian cancer. EJSO; 2011:6: IF: 2.499

6 Area 3. CARCINOMATOSIS PERITONEAL

7 Area 3. CARCINOMATOSIS PERITONEAL

8 Area 3. CARCINOMATOSIS PERITONEAL
Cascales P, Lopez V, Gil J and GECOP. Morbidity And Mortality Outcomes After Cytoreductive Surgery And Hyperthermic Intraperitoneal Chemotherapy In Patients Aged 75 Years And Over: Spanish Group Of Peritoneal Cancer Surgery (GECOP) Multicenter Study. Surgical Oncology 2016 (in press)

9 PUBLICACIONES ÚLTIMOS 5 AÑOS (RESUMEN)
Area 3. CARCINOMATOSIS PERITONEAL PUBLICACIONES ÚLTIMOS 5 AÑOS (RESUMEN) 19 PUBLICACIONES de CP 16-Q1 SURGICAL ONCOLOGY (2) DIS COLON AND RECTUM (1) ANNALS OF SURGICAL ONCOLOGY (2) EJSO (2) BRITISH JOURNAL OF RADIOLOGY (1) GYNECOLOGIC ONCOLOGY (1) EJORGB (3)

10 Area 3. CARCINOMATOSIS PERITONEAL
2016 PAPERS ONGONIG….. PROGRAMA DE FAST-TRACK 1. RESULTADOS GLOBALES DEL PROTOCOLO 2. IMPACTO DEL FAST-TRACK EN RELACIÓN AL CONTROL HISTÓRICO 3. MORBILIDAD TRAS EXTENTERACIONES POSTERIORES + HIPEC 4. INFLUENCIA DEL IMC EN LOS R ESULTADOS QUIÚRGICOS Y PRONÓSTICOS 5. VALOR PREOPERATORIO DEL TC Y PET-TC EN PACIENTES CON CP. 6. CP OVÁRICO PRIMARIO. MULTICÉNTRICO (GECOP) 7. REVIEW CCR + HIPEC EN ANCIANOS 8. COLORATA 1: ANASTOMOSIS Y HIPEC 10

11 Area 3. CARCINOMATOSIS PERITONEAL
PROYECTOS CLÍNICOS

12 Area 3. CARCINOMATOSIS PERITONEAL

13 Area 3. CARCINOMATOSIS PERITONEAL

14 Area 3. CARCINOMATOSIS PERITONEAL
HIPEC

15 PROYECTOS CLÍNICO-BÁSICOS
Area 3. CARCINOMATOSIS PERITONEAL PROYECTOS CLÍNICO-BÁSICOS

16 Area 3. CARCINOMATOSIS PERITONEAL
CONEXIONES CLÍNICOS-BÁSICOS GRUPO DE INVESTIGACIÓN EN CIRUGÍA ONCOLÓGICA PERITONEAL COLORATA 1: ANASTOMOSIS Y HIPEC COLORATA 2: MAPING DE LAS HSPs COLORATA 3: DESARROLLO DE MODELOS DE CP EN ROEDORES PROYECTO RENO. Immunological profile in patients with epithelial ovarian cancer. FIS-PI13/02297. ENSAYO CLÍNICO (NCT ). CONDICIONES HIPEC IN VITRO.

17 Area 3. CARCINOMATOSIS PERITONEAL
COLORATA 1

18 Area 3. CARCINOMATOSIS PERITONEAL
COLORATA 1

19 Area 3. CARCINOMATOSIS PERITONEAL
COLORATA 1

20 Area 3. CARCINOMATOSIS PERITONEAL
COLORATA 1 PRESIONES DE ROTURA

21 RENO project FIS-PI13/02297 project

22